Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy

European Respiratory Journal

Volumn 43, Issue 5, 2014, Pages 1513-1515

  Harbaum, Lars ^a   Hennigs, Jan K ^a,b   Baumann, Hans J ^a   Bokemeyer, Carsten ^a   Olschewski, Horst ^c   Klose, Hans ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DILTIAZEM; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; B CELL LYMPHOMA; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HEART CATHETERIZATION; HEART INDEX; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SALVAGE THERAPY; TREATMENT DURATION; COMPLICATION; DISEASE COURSE; HEMODYNAMICS; LYMPHOMA, B-CELL; PROGNOSIS; TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LYMPHOMA, B-CELL; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899855242     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00185713     Document Type: Letter

References (15)

1. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
2. Rai PR, Cool CD, King JA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 558-564.
3. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012; 122: 4306-4313.
4. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
5. Adir Y, Humbert M. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir J 2010; 35: 1396-1406.
6. Marvin KS, Spellberg RD. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest 1993; 103: 642-644.
7. Kotake T, Kosugi S, Takimoto T, et al. Intravascular large B-cell lymphoma presenting pulmonary arterial hypertension as an initial manifestation. Intern Med 2010; 49: 51-54.
8. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe precapillary pulmonary hypertension? BMC Pulm Med 2011; 11: 30.
9. Jonigk D, Golpon H, Bockmeyer CL, et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011; 179: 167-179.
10. Asosingh K, Farha S, Lichtin A, et al. Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension. Blood 2012; 120: 1218-1227.
11. Farha S, Asosingh K, Xu W, et al. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood 2011; 117: 3485-3493.
12. Igreja C, Courinha M, Cachaco AS, et al. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 2007; 92: 469-477.
13. Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 2008; 17: 754-756.
14. Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, et al. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease. Clin Exp Rheumatol 2013; 31: 657-658.
15. Mizuno S, Farkas L, Al Husseini A, et al. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. Am J Respir Cell Mol Biol 2012; 47: 679-687.